A functional scaffold in marine alkaloid: An anticancer moiety for human

Current Medicinal Chemistry

Volumn 20, Issue 31, 2013, Pages 3903-3922

  Li, X ^a   Li, Jing Ran ^a   Chen, Kun ^a,b   Zhu, Hai Liang ^a  

^a NANJING UNIVERSITY   (China)

^b GUANGZHOU UNIVERSITY   (China)

Author keywords

Anticancer agents; Anticancer mechanisms; Docking analysis; Marine alkaloids; Structure activity studies

Indexed keywords

ALKALOID; ANTINEOPLASTIC AGENT; DNA TOPOISOMERASE; DNA TOPOISOMERASE (ATP HYDROLYSING); INDOLE ALKALOID; OXAZOLE; PALBOCICLIB; PYRAZOLE; PYRIDINE; PYRROLOQUINON; THIAZOLE; TIAZOFURIN; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CANCER; CELL CYCLE ARREST; COLON CANCER; ENZYME ACTIVITY; HUMAN; HYDROGEN BOND; LUNG CANCER; MARINE SPECIES; MOLECULAR DOCKING; MOLECULAR RECOGNITION; PANCREAS CANCER; PROSTATE CANCER; STRUCTURE ACTIVITY RELATION;

ALKALOIDS; ANIMALS; ANTINEOPLASTIC AGENTS; HUMANS; INDOLES; NEOPLASMS; OXAZOLES; PYRIDINES; PYRROLES; QUINOLINES;

EID: 84887975932     PISSN: 09298673     EISSN: 1875533X     Source Type: Journal    
DOI: 10.2174/09298673113209990186     Document Type: Article

References (141)

1. Argelia Lorence.; Craig L. Nessler. Molecules of Interest Camptothecin, over four decades of surprising findings. Phytochemistry, 2004, 65, (20), 2735-2749
2. Facchini. ALKALOID BIOSYNTHESIS IN PLANTS : Biochemistry, Cell Biology, Molecular Regulation, and Metabolic Engineering Applications. Annual Review of Plant Physiology and Plant Molecular Biology. 2001, 52, (1), 29-66
3. Yang, Liuqing.; Stèockigt.;Joachim. Trends for diverse production strategies of plant medicinal alkaloids. Natural Product Reports. 2010, 27, (10), 1469-1479
4. Bruce. Engineering pathways for transformations of morphine alkaloids. Trends in Biotechnology. 1995, 13, (6), 200-205
5. Jordan. Mechanism of mitotic block and inhibition of cell proliferation by taxol at low concentrations. Proceedings of the National Academy of Sciences-PNAS. 1993, 90, (20), 9552
6. Wilson. New microtubule/tubulin-targeted anticancer drugs and novel chemotherapeutic strategies. Journal of Chemotherapy. 2004, 16, 83
7. Lorence. Camptothecin, over four decades of surprising findings. Phytochemistry. 2004, 65, (20).
8. Dzhakhangirov. Diterpenoid alkaloids as a new class of antiarrhythmic agents. Chemistry of Natural Compounds. 1997, 33, (2), 190-202.
9. Pennington. Belladonna alkaloids and immer rbital combination pharmaceuticals analysis I: High-performance liquid chromatographic determinations of hyoscyamine-atropine and scopolamine. Journal of Pharmaceutical Sciences. 1982, 71, (8), 951-953.
10. Molinski. Marine pyridoacridine alkaloids: structure, synthesis, and biological chemistry. Chemical Reviews. 1993, 93, (5), 1825-1838
11. Delfourne. Marine pyridoacridine alkaloids and synthetic analogues as antitumor agents. Medicinal Research Reviews. 2003, 23, (2), 234-252
12. Dembitsky. Novel antitumor agents: Marine sponge alkaloids, their synthetic analogs and derivatives. Mini-Reviews in Medicinal Chemistry. 2005, 5, (3), 319.
13. Delfourne. Marine pyridoacridine alkaloids and synthetic analogues as antitumor agents. Medicinal Research Reviews. 2003, 23, (2), 234-252.
14. Wallace Hayes. Mycotoxins: A review of biological effects and their role in human diseases. Clinical Toxicology. 1980,17, (1), 45-83.
15. Rateb.; Mostafa E.; Ebel, Rainer. Secondary metabolites of fungi from marine habitats. Natural Product Reports. 2011, 28, (2), 290-344.
16. Zhou, X .; Yang, X. Review. Chemistry and Biodiversity. 2010, 7, (12).
17. Jiang, C.-S.; Guo, Y.-W. Epipolythiodioxopiperazines from Fungi: Chemistry and Bioactivities. Mini-Reviews in Medicinal Chemistry. 11, (9), 2011, 728-745.
18. Lu, Y.; Li, C.-M.; Wang, Z. Design, Synthesis, and SAR Studies of 4-Substituted Methoxylbenzoyl-aryl-thiazoles Analogues as Potent and Orally Bioavailable Anticancer Agents. Journal of Medicinal Chemistry. 2011, 54 (13), 4678-4693.
19. Kumar D.; Kumar N. M.; Sundaree S.; Johnson E. O.; Shah K. An expeditious synthesis and anticancer activity of novel 4-(3'-indolyl) oxazoles. European Journal of Medicinal Chemistry. 2010, 45 (3), 1244-1249.
20. Biersack, B.; Effenberger, K.; Schobert, R.; Ocker, M. Oxazole-Bridged Combretastatin A Analogues with Improved Anticancer Properties. Chemmedchem. 2010, 5 (3), 420-427.
21. Dugan, B. J.; Gingrich, D. E.; Mesaros, E. F. A Selective, Orally Bioavailable 1, 2, 4-Triazolo [1, 5-a] pyridine-Based Inhibitor of Janus Kinase 2 for Use in Anticancer Therapy: Discovery of CEP-33779. Journal of Medicinal Chemistry. 2012, 55 (11), 5243-5254.
22. Elzahabi, H. S. Synthesis, characterization of some benzazoles bearing pyridine moiety: Search for novel anticancer agents. European Journal of Medicinal Chemistry. 2011, 46(9), 4025-4034.
23. Ahmad, A.; Sakr, W. A.; Rahman, K. M. W. Anticancer Properties of Indole Compounds: Mechanism of Apoptosis Induction and Role in Chemotherapy. Current Drug Targets. 2010, 11 (6), 652-666.
24. Selen Gurkan-Alp A .; Buyukbingol E .; Mumcuoglu M .; Dayanc E .; Cetin-Atalay R. Synthesis, anticancer activities and molecular modeling studies of novel indole retinoid derivatives. European Journal of Medicinal Chemistry. 2012, 58, 346-354.
25. Gompel. Meridianins, a new family of protein kinase inhibitors isolated from the Ascidian Aplidium meridianum. Bioorganic and Medicinal Chemistry Letters. 2004, 14, (7), 1703-1707.
26. Zhu. Synthesis, StructureActivity Relationship, and Biological Studies of Indolocarbazoles as Potent Cyclin D1-CDK4 Inhibitors. Journal of Medicinal Chemistry. 2003, 46 (11), 2027-2030.
27. Newman. Marine Natural Products and Related Compounds in Clinical and Advanced Preclinical Trials. Journal of Natural Products. 2004, 67, (8), 1216-1238.
28. Patel K.; Gadewar M.; Tripathi R.; Prasad S.K.; Patel D.K. A review on medicinal importance, pharmacological activity and bioanalytical aspects of beta-carboline alkaloid. Asian Pacific Journal of Tropical Biomedicine. 2012, 2, (8), 660-664.
29. Socha, A.M.; Long, R.A.; Rowley, D.C. Bacillamides from a Hypersaline Microbial Mat Bacterium. Journal of Natural Products. 2007, 70, (11), 1793-1795.
30. Yu, L. L.; Li, Z. Y.; Peng, C. S. Neobacillamide A, a Novel Thiazole-Containing Alkaloid from the Marine Bacterium Bacillus vallismortis C89, Associated with South China Sea Sponge Dysidea avara. Helvetica Chimica Acta. 2009, 92, (3), 607-612
31. Davyt. Thiazole and Oxazole Alkaloids: Isolation and Synthesis. Marine Drugs. 2010, 8, (11), 2755-2780.
32. Wang, Wei; Joyner, Shannon; Khoury, Kareem Andrew Sameer; Dè omling. (-)-Bacillamide C: the convergent approach. Organic and Biomolecular Chemistry. 2010, 8, (3), 529-532.
33. Raveh A.; Carmeli S.; Moshe S.; Evron Z.; Flescher E. Novel thiazole and oxazole containing cyclic hexapeptides from a waterbloom of the cyanobacterium Microcystis sp. Tetrahedron. 2010, 66, (14), 2705-2712.
34. Kwan, J. C.; Ratnayake, R.; Abboud, K. A.; Paul, V. J.; Luesch, H. Grassypeptolides A-C, Cytotoxic Bis-thiazoline Containing Marine Cyclodepsipeptides. Journal of Organic Chemistry. 2010, 75, (23), 8012-8023.
35. Liu, H.; Liu, Y.; Xing, X. Total synthesis of grassypeptolide. Chemical Communications. 2010, 46, (40), 7486-7488
36. Thornburg, C. C .; Thimmaiah, M .; Shaala, L. A .; Hau, A. M .; Malmo, J. M .; Ishmael, J. E. Cyclic Depsipeptides, Grassypeptolides D and E and Ibu-epidemethoxylyngbyastatin 3, from a Red Sea Leptolyngbya Cyanobacterium. Journal of Natural Products. 2011, 74, (8), 1677-1685.
37. Narender. Aqueous phase synthesis of thiazoles and aminothiazoles in the presence of-cyclodextrin. Tetrahedron Letters. 2005, 46, (35), 5953-5955.
38. Saeed, S.; Wong, W. T. A Simple, Convenient, and Efficient Synthetic Route for The Preparation of (Z)-3,5-Dichloro-N-(3-(4-substitutedphenyl)-4- phenylthiazole-2(3H)-ylide) benzamide Heterocyclic Compounds from Aroyl Thiourea Derivatives via Scyclization Mechanis. Journal of Heterocyclic Chemistry. 2012, 49, (3), 580-584.
39. Peter J. O'Dwyer.; D. Dale Shoemaker.; Hiremagalur N. Tiazofurin: A new antitumor agent. Investigational New Drugs. 1984, 2,79-84.
40. Jayaram HN.; Dion RL.; Glazer RI.; Johns DG. Initial studies on the mechanism of action of a new oncolytic thiazole nucleoside, 2-/3- Dribofuranosylthiazole-4-carboxamide (NSC 286193). Biochem Pharmacol. 1982, 31, 2371-2380
41. Gebeyehu G.; Marquez VE.; Kelley JA. Synthesis of thiazole-4- carboxamideadenine dinucleotide (TAD). A powerful inhibitor of IMP dehydrogenase. J Med Chem. 1983, 26, 922-925.
42. Chang S .; Zhang Z .; Zhuang X .; Luo J .; Tu Z .; Lu X .; Ren X .; Ding K.; Cao X .; Li H. New thiazole carboxamides as potent inhibitors of Akt kinases. Bioorganic and Medicinal Chemistry Letters. 2012, 22, (2), 1208-1212.
43. Scheid. PKB/AKT: FUNCTIONAL INSIGHTS FROM GENETIC MODELS. Nature Reviews-Molecular Cell Biology. 2001, 2, (10), 760-768.
44. Song. The activation of Akt/PKB signaling pathway and cell survival. Journal of Cellular and Molecular Medicine. 2005, 9, (1), 59-71.
45. Vivanco. The phosphatidylinositol 3-Kinase-AKT pathway in human cancer. Nature Reviews-Cancer. 2002, 2, 489-501.
46. Sansal. The Biology and Clinical Relevance of the PTEN Tumor Suppressor Pathway. Journal of Clinical Oncology. 2004, 22, (14), 2954-2963.
47. Frederick. Conformational entropy in molecular recognition by proteins. Nature. 2007, 448, 325-329.
48. Alvarez. High-throughput docking as a source of novel drug leads. Current Opinion in Chemical Biology. 2004, 8 (4), 365-370.
49. Fu. Makaluvic Acids A and B: Novel Alkaloids from the Marine Sponge Zyzzya fuliginosus. Journal of Natural Products. 1996, 59, (11), 1104-1106.
50. Ding. Pyrroloquinoline and pyridoacridine alkaloids from marine sources. Current Medicinal Chemistry. 1999, 6, (1), 1.
51. Molinski. Marine pyridoacridine alkaloids: structure, synthesis, and biological chemistry. Chemical Reviews. 1993, 93, (5), 1825-1838.
52. Antunes. Pyrroloiminoquinone and related metabolites from marine sponges. Natural Product Reports. 2005, 22, (1), 62.
53. Delfourne, E. Analogues of Marine Pyrroloiminoquinone Alkaloids: Synthesis and Antitumor Properties. Anti-Cancer Agents in Medicinal Chemistry. 2008, 8, (8), 910-916.
54. Chang. Batzelline D and Isobatzelline E from the Indopacific Sponge Zyzzya f uliginosa. Journal of Natural Products. 2002, 65, (5), 776-778.
55. Nag. Anticancer Activity and Molecular Mechanisms of Action of Makaluvamines and Analogues Molecular and Cellular Pharmacology. 2012, 4 (2), 69
56. White. Synthetic Studies of the Pyrroloquinoline Nucleus of the Makaluvamine Alkaloids. Synthesis of the Topoisomerase II Inhibitor Makaluvamine D. Journal of the American Chemical Society. 1994, 116, (5), 1831-1838.
57. Radisky. Novel cytotoxic topoisomerase II inhibiting pyrroloiminoquinones from Fijian sponges of the genus Zyzzya. Journal of the American Chemical Society. 1993, 115, (5), 1632-1638.
58. Ahmad M. Faraga.; Abdelrahman S. Mayhoubb.; Saber E. Barakatb.; Ashraf H. Bayomic. Regioselective synthesis and antitumor screening of some novel N-phenylpyrazole derivatives. Bioorganic & Medicinal Chemistry. 2008, 16, (2), 881-889.
59. Pommier. DNA topoisomerase I and II in cancer chemotherapy: update and perspectives. Cancer Chemotherapy and Pharmacology. 1993, 32, (2), 103-108.
60. Kathiravan. Topoisomerase as target for antibacterial and anticancer drug discovery. Journal of Enzyme Inhibition and Medicinal Chemistry. 2012, 1, 1-17.
61. Topcu. DNA topoisomerases as targets for anticancer drugs. Journal of Clinical Pharmacy and Therapeutics. 2001, 26, (6), 405-416.
62. Kaneoka H .; Miyake K .; Iijima S . Interactions between the nuclear matrix and an enhancer of the tryptophan oxygenase gene. Biochemical and Biophysical Research Communications. 2009, 387 (4), 717-722
63. Charvin. Tracking topoisomerases activity at the single molecule level. Annual Review of Biophysics. 2005, 34 (1), 201-219.
64. Legentil. Synthesis and Antitumor Characterization of Pyrazolic Analogues of the Marine Pyrroloquinoline Alkaloids: Wakayin and Tsitsikammamines. Journal of Medicinal Chemistry. 2006, 49(10), 2979-2988.
65. Dassonneville, L.; Wattez, N.; Baldeyrou, B.; Mahieu, C.; Lansiaux, A.; Banaigs, B.; Bonnard, I.; Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem. Pharmacol. 2000, 60, 527-537.
66. Bidhan A.;,Shinkre.; Kevin P. Raisch.; Analogs of the marine alkaloid makaluvamines: Synthesis,topoisomerase II inhibition, and anticancer activity. Bioorganic & Medicinal Chemistry Letters. 2007, 17, 2890-2893.
67. Vistica. Tetrazolium-based assays for cellular viability: a critical examination of selected parameters affecting formazan production. Cancer Research. 1991, 51 (10), 2515.
68. Wei Wang. In vitro and In vivo Anticancer Activity of Novel Synthetic Makaluvamine Analogues. Clinical Cancer Research. 2009, 15 (10), 1078-0432.
69. Twentyman. A study of some variables in a tetrazolium dye (MTT) based assay for cell growth and chemosensitivity. British Journal of Cancer. 1987, 56 (3), 279.
70. Jacob. The role of the DNA mismatch repair system in the cytotoxicity of the topoisomerase inhibitors camptothecin and etoposide to human colorectal cancer cells. Cancer Research. 2001, 61 (17) 6555.
71. Fink. The role of DNA mismatch repair in drug resistance. Clinical Cancer Research. 1998, 4 (1), 1078-0432.
72. Jin, Zhong. Muscarine, imidazole, oxazole and thiazole alkaloids. Natural Product Reports. 2009, 26, (3), 382-445.
73. Wright. Neopeltolide, a Macrolide from a Lithistid Sponge of the Family Neopeltidae. Journal of Natural Products. 2007, 70, (3), 412-416.
74. Paterson, Ian; Miller, Natalie A. Total synthesis of the marine macrolide (+)-neopeltolide. Chemical Communications. 2008, 39, 4708-4710.
75. Bishara, A.; Rudi, A.; Aknin, M.; Neumann, D.; Ben-Califa, N.; Kashman, Y. Taumycins A and B, Two Bioactive Lipodepsipeptides from the Madagascar Sponge Fascaplysinopsis sp. Organic Letters 2008, 10, (19), 4307-4310.
76. Fernandez R.; Martin M. J.; Rodriguez-Acebes R.; Reyes F.; Francesch A.; Cuevas C. Diazonamides C-E, new cytotoxic metabolites from the ascidian Diazona sp. Tetrahedron Letters 2008, 49, (14), 2283-2285.
77. Zhang, J.; Ciufolini, M. A. Total Synthesis of Siphonazoles by the Use of a Conjunctive Oxazole Building Block. Organic Letters. 2009, 11, (11), 2389-2392.
78. G Ravelo. Recent Studies on Natural Products as Anticancer Agents. Current Topics in Medicinal Chemistry. 2004, 4, (2), 241-265.
79. Whitfield. Identification of genes periodically expressed in the human cell cycle and their expression in tumors. Molecular Biology of the Cell. 2002, 13, (6), 1977.
80. Oxberry. Individual Expression of Recombinant-and-Tubulin from Haemonchus contortus: Polymerization and Drug Effects. Protein Expression and Purification. 2001, 21, (1), 30-39.
81. Waterman-Storer. Microtubule dynamics: Treadmilling comes around again. Current Biology. 1997, 7, (6), R369-R372.
82. Kingston, D. G. I. Tubulin-Interactive Natural Products as Anticancer Agents. Journal of Natural Products 2009, 72, (3), 507-515.
83. Ouyang. Oxadiazole derivatives as a novel class of antimitotic agents: Synthesis, inhibition of tubulin polymerization, and activity in tumor cell lines. Bioorganic and Medicinal Chemistry Letters. 2006, 16, (5), 1191-1196.
84. Hamel, E. Cell Biochem. Biophys. 2003, 38, 1.
85. Pozo-Guisado. The antiproliferative activity of resveratrol results in apoptosis in MCF-7 but not in MDA-MB-231 human breast cancer cells: cell-specific alteration of the cell cycle. Biochemical Pharmacology. 2002, 64 (9), 1375-1386.
86. D.A. Scudiero, R.H. Shoemaker, K.D. Paull, A. Monks, S. Tierney, T.H. Nofziger, M.J. Currens, D. Seniff, M.R. Boyd. Cancer Res. 1988, 48, 4827.
87. Yamazaki, Y.; Kohno, K.; Yasui, H.; Kiso, Y.; Akamatsu, M.; Nicholson, B.; Deyanat-Yazdi, G.; Neuteboom, S.; Potts, B.; Lloyd, G. K. Tubulin Photoaffinity Labeling with Biotin-Tagged Derivatives of Potent Diketopiperazine Antimicrotubule Agents. Chembiochem. 2008, 9, (18), 3074-3081.
88. Yamazaki Y.; Yakushiji F.; Hayashi Y.; Sumikura M.; Hidaka K.; Kiso Y.; Yasui H. Bioorganic and Medicinal Chemistry. 2010, 18, (9), 3169-3174.
89. G. Dorman, G.D. Prestwich. Trends Biotechnol. 2000, 18, 64.
90. Dembitsky. Novel antitumor agents: Marine sponge alkaloids, their synthetic analogs and derivatives. Mini-Reviews in Medicinal Chemistry. 2005, 5, (3), 319.
91. Merschjohann. In Vitro Effect of Alkaloids on Bloodstream Forms of Trypanosoma brucei and T. congolense. Planta Medica. 2001, 67, (7), 623-627.
92. Delfourne. Synthesis and Characterization of the Antitumor Activities of Analogues of Meridine, a Marine Pyridoacridine Alkaloid. Journal of Medicinal Chemistry. 2001, 44, (20), 3275-3282.
93. Bracher. 3-Alkylpyridines III. Total synthesis of both enantiomers of the antineoplastic marine alkaloid niphatesine D. Monatshefte Für Chemie. 1996, 127, (1), 91-95.
94. Jun'ichi Kobayashi.; Tetsuya Murayama. Niphatesines A-D, new antineoplastic pyridine alkaloids from the okinawan marine sponge Niphates sp. J. Chem. Soc.Perkin Trans. 1990, 1, 3301-3303
95. Burres. Antitumor activity and nucleic acid binding properties of dercitin, a new acridine alkaloid isolated from a marine Dercitus species sponge. Cancer Research. 1989, 49, (19), 5267.
96. Groundwater. Advances in Heterocyclic Chemistry. 1997, 70, 90-162.
97. Matsugana, S.; Okada, Y.; Fusetani, N. An antimicrobial C14 acetylenic acid from a marine sponge Oceanapia species. J. Nat. Prod. 2000, 63, 690-691.
98. Turk. Mechanisms of Toxicity of 3-Alkylpyridinium Polymers from Marine Sponge Reniera sarai. Marine Drugs. 2007, 5, (4), 157-167.
99. Anake Kijjoa.; Rawiwan Wattanadilok. Anticancer Activity Evaluation of Kuanoniamines A and C Isolated from the Marine Sponge Oceanapia sagittaria, Collected from the Gulf of Thailand. Mar. Drugs. 2007, 5, 6-22.
100. Sharma, P. S.; Sharma, R.; Tyagi, R. Inhibitors of Cyclin Dependent Kinases: Useful Targets for Cancer Treatment. Current Cancer Drug Targets. 2008, 8, (1), 53-75.
101. Moriarty. Topics in Medicinal Chemistry. 2006, 1, 207-291.
102. Kong. Cell cycle inhibitors for the treatment of cancer. Drugs of the Future. 2003, 28 (9), 881
103. Ian Collins.; Michelle D Garrett. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Current Opinion in Pharmacology. 2005, 5(4), 366-373.
104. Pevarello. Cyclin-dependent kinase inhibitors: a survey of the recent patent literature. Expert Opinion on Therapeutic Patents. 2005, 15, (6), 675-70.
105. D.W. Fry.; P.J. Harvey.; P.R. Keller. Specific inhibition of cyclindependent kinase 4/6 by PD 0332991 and associated antitumour activity in human tumor xenografts. Mol Cancer Ther. 2004, 3, 1427-1437
106. Malumbres. Cell cycle kinases in cancer. Current Opinion in Genetics and Development. 2007, 17, (1), 60-65.
107. Johansson, M.; Persson, J. L. Cancer Therapy: Targeting Cell Cycle Regulators. Anti-Cancer Agents in Medicinal Chemistry. 2008, 8, (7), 723-731.
108. Cover. Indole-3-carbinol and tamoxifen cooperate to arrest the cell cycle of MCF-7 human breast cancer cells. Cancer Research. 1999, 59, (6), 1244.
109. Niefind. Crystal structure of human protein kinase CK2: insights into basic properties of the CK2 holoenzyme. EMBO Journal, 2001, 20, (19), 5320-5331.
110. Gray. ATP-site directed inhibitors of cyclin-dependent kinases. Current Medicinal Chemistry. 1999, 6 (9), 859
111. Tong. A highly specific inhibitor of human p38 MAP kinase binds in the ATP pocket. Nature Structural Biology. 1997, 4, (4), 311-316.
112. Cai. AZ703, an Imidazo[1,2-a]Pyridine Inhibitor of Cyclin-Dependent Kinases 1 and 2, Induces E2F-1-Dependent Apoptosis Enhanced by Depletion of Cyclin-Dependent Kinase 9. Cancer Research. 2006, 66, (1), 435-444.
113. Misra. 1H-Pyrazolo[3,4-b]pyridine inhibitors of cyclin-dependent kinases: highly potent 2,6-Difluorophenacyl analogues. Bioorganic and Medicinal Chemistry Letters. 2003, 13 (14), 2405-2408.
114. Collins. Targeting the cell division cycle in cancer: CDK and cell cycle checkpoint kinase inhibitors. Current Opinion in Pharmacology. 2005, 5, (4), 366-373.
115. Jacquemard U.; Dias N.; Lansiaux A .; Bailly C.; Loge C.; Robert J.-M.; Lozach O.; Meijer L.; Merour J.-Y .; Routier S. Synthesis of 3, 5-bis (2-indolyl) pyridine and 3-[ (2-indolyl)-5-phenyl] pyridine derivatives as CDK inhibitors and cytotoxic agents. Bioorganic and Medicinal Chemistry 2008, 16, (9), 4932-4953.
116. P. Furet. Anti-Cancer Agents. Curr. Med. Chem. 2003, 3, 15-23.
117. K.F. Byth.; N. Cooper.; J.D. Culshaw. Bioorg. Med. Chem. Lett. 2004, 14, 2249-2252.
118. S. Verma.; D. Nagarathnam.; J. Shao. Bioorg. Med. Chem. Lett. 2005, 15, 1973-1977.
119. Gul. Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life Sciences. 2005, 78, (5), 442-453.
120. Carney. Makaluvamine G, a cytotoxic pigment from an an Indonesian Sponge Histodermella sp. Tetrahedron. 1993, 49, (38), 8483-8486.
121. Kohmoto. Dragmacidin, a new cytotoxic bis(indole) alkaloid from a deep water marine sponge, Dragmacidon sp. Journal of Organic Chemistry. 1988, 53, (13), 3116-3118.
122. Yang. Preparing Functional Bis(indole) Pyrazine by Stepwise Cross-coupling Reactions: An Efficient Method to Construct the Skeleton of Dragmacidin D. Journal of Organic Chemistry. The 2002, 67, (26), 9392-9396.
123. Capon. Dragmacidins: New Protein Phosphatase Inhibitors from a Southern Australian Deep-Water Marine Sponge, Spongosorites sp. Journal of Natural Products. 1998, 61, (5), 660-662.
124. Waseem Gul.; Mark T. Hamann Indole alkaloid marine natural products: An established source of cancer drug leads with considerable promise for the control of parasitic, neurological and other diseases. Life Sciences. 2005, 5(22), 442-453.
125. Balamurugan. Design of compound libraries based on natural product scaffolds and protein structure similarity clustering (PSSC). Molecular Biosystems. 2005, 1, (1), 36.
126. Garikapaty. Synthetic immer of indole-3-carbinol: Second generation diet derived anti-cancer agent in hormone sensitive prostate cancer. Prostate. 2006, 66 (5), 453-462
127. Chao. Computer-Aided Rational Drug Design: A Novel Agent (SR13668) Designed to Mimic the Unique Anticancer Mechanisms of Dietary Indole-3-Carbinol to Block Akt Signaling. Journal of Medicinal Chemistry. 2007, 50, (15), 3412-3415.
128. Zeligs MA.; Sepkovic DW. Absorption-enhanced 3,3-Diindolylmethane: human use in HPV-related, benign and precancerous conditions. American Association of Cancer Research. 2002, 42.
129. Rosen CA.; Woodson GE.; Thompson JW. Preliminary results of the use of indole-3-carbinol for recurrent respiratory papillomatosis. Otolaryngol Head Neck Surg. 1998, 118(6), 810.
130. d'Argy R.; Bergman J.; Dencker L.; Effects of immunosuppressive chemicals on lymphoid development in foetal thymus organ cultures. Pharmacol Toxicol. 1989, 64(1), 33.
131. Medjakovic. Phytoestrogens and their Putative Effects on the Aryl Hydrocarbon Receptor. Current Bioactive Compounds. 2011, 7, (3), 136-155.
132. Safe. Molecular biology of the Ah receptor and its role in carcinogenesis. Toxicology Letters. 2001,120, 1-7.
133. Aggarwal. Molecular Targets and Anticancer Potential of Indole-3-Carbinol and Its Derivatives. Cell Cycle. 2005, 4, (9), 1201-1215.
134. Shen, Han-Ming; Tergaonkar. Vinay. Apoptosis. 2009, 14, (4), 348-363.
135. Banerjee S.; Kong D.; Wang Z.; Bao B.; Hillman G. G.; Sarkar F. H. Attenuation of multi-targeted proliferation-linked signaling by 3, 3'-diindolylmethane (DIM): From bench to clinic. Mutation Research. Reviews in Mutation Research. 2011, 728, 47-66.
136. Weng J.-R.; Tsai C.-H.; Kulp S. K.; Chen C.-S. Indole-3-carbinol as a chemopreventive and anti-cancer agent. Cancer Letters. 2008, 262, (2), 153-163.
137. Kim. Targets for indole-3-carbinol in cancer prevention. Journal of Nutritional Biochemistry. 2005, 16, (2), 65-73.
138. Weng, J.-R.; Omar, H. A.; Kulp, S. K.; Chen, C.-S. Pharmacological Exploitation of Indole-3-Carbinol to Develop Potent Antitumor Agents. Mini-Reviews in Medicinal Chemistry. 2010, 10, (5), 398-404.
139. Chao. Computer-Aided Rational Drug Design: A Novel Agent (SR13668) Designed to Mimic the Unique Anticancer Mechanisms of Dietary Indole-3-Carbinol to Block Akt Signaling. Journal of Medicinal Chemistry. 2007, 50 (15), 12-3415
140. Reid. Phase 0 Clinical Chemoprevention Trial of the Akt Inhibitor SR13668. Cancer Prevention Research. 2011, 4, (3), 347-353.
141. Dassonneville, L.; Wattez, N.; Baldeyrou, B.; Mahieu, C.; Lansiaux, A.; Banaigs, B.; Bonnard, I.; Bailly, C. Inhibition of topoisomerase II by the marine alkaloid ascididemin and induction of apoptosis in leukemia cells. Biochem. Pharmacol. 2000, 60, 527-537.